Mobile

Study to compare Umeclidinium when added to FP/SAL versus placebo when added to FP/SAL in COPD Patients. Hodnocení srovnávající Umeclidinium přidané k FP/SAL oproti placebu přidanému k FP/SAL u ...

Update Il y a 5 ans
Reference: EUCTR2012-001871-35

Study to compare Umeclidinium when added to FP/SAL versus placebo when added to FP/SAL in COPD Patients. Hodnocení srovnávající Umeclidinium přidané k FP/SAL oproti placebu přidanému k FP/SAL u pacientů s CHOPN

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective is to compare the efficacy and safety of the addition of UMEC (62.5mcg) once-daily to FSC (250/50mcg) twice-daily, UMEC (125mcg) once-daily to FSC (250/50mcg) twice-daily with placebo to FSC (250/50mcg) twice-daily over 12 weeks for the treatment of subjects with COPD.

Inclusion criteria

  • Chronic Obstructive Pulmonary Disease (COPD)

Links